Actinium Pharmaceuticals, Inc. (ATNM)

NYSEAMERICAN: ATNM · USD

$1.37

-0.05 (-3.5%)· Recorded snapshot

Market cap	43.1M
Revenue (ttm)	35.1M
Net income (ttm)	11.3M
EPS (ttm)	$0.36
Shares out	31.4M
P/E (trailing)	3.8x
Volume	53,630
Beta	0.27

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 35.1M
Net income (ttm): 11.3M
EPS (ttm): $0.36
P/E (trailing): 3.8x
Market cap: 43.1M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Держать

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/E3.8

P25 15.4P50 25.8P75 43.5

ROE45.9

P25 -113.8P50 -46.5P75 -0.9

ROIC23

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All ATNM indicators

Market & fundamental data

Available fields

212

Groups with data

Currency

USD

Showing 212 of 212 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001388320
Company name	Actinium Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	00507W206
Earnings date	2026-11-13
Earnings time	amc
Employees	27
Employees change	0
Employees growth	0%
Enterprise value	$7.9M
Exchange	NYSEAMERICAN
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US00507W2061
Last 10-K release date	2026-03-30
Last earnings date	2026-08-07
Last refreshed	2026-10-28
Last stock split date	2020-08-11
Last stock split type	Reverse
Market cap	$43.1M
Market cap category	Nano-Cap
Next earnings date	2026-11-13
Options	Yes
Price	$1.37
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ATNM
U.S. state	New York
Website	https://www.actiniumpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	3.81x
Earnings yield	25.98%
EV/Earnings	0.84x
EV/EBIT	1x
EV/EBITDA	0.97x
EV/Sales	0.27x
FCF / EV yield	-244.32%
FCF yield	-52.07%
Graham number	2.778
Graham upside	95.63%
P/B ratio	1.47x
P/E ratio	3.85x
P/S ratio	1.27x
Price / tangible book value	1.47x
Price/EBITDA ratio	4.56x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	27.23%
EBITDA margin	27.9%
Gross margin	100%
Operating margin	27.23%
Pretax margin	32.23%
Profit margin	32.23%
Profit per employee	$418,815
Profitable quarters	1
Revenue per employee	$1.3M
ROA	11.58%
ROA (5Y)	-28.96%
ROCE	30.93%
ROE	45.86%
ROE (5Y)	-91.28%
ROIC	23%
SBC / revenue	0.71%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	5
EPS growth years	2
Gross profit growth 3Y	820.43%
Gross profit growth 5Y	108.62%
Net income growth quarters	5
Net income growth years	2
Revenue growth 3Y	820.43%
Revenue growth 5Y	108.62%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-584,000
Depreciation and amortization	$235,000
EBIT	$9.6M
EBITDA	$9.8M
EPS	$0.36
FCF per share	$-0.74
Financing cash flow	$-217,000
Free cash flow	$-23.2M
Free cash flow minus SBC	$-23.5M
Gross profit	$35.1M
Investing cash flow	$-584,000
Net borrowing	$-10,000
Net cash flow	$-23.4M
Net income	$11.3M
Operating cash flow minus SBC	$-22.9M
Operating income	$9.6M
Revenue	$35.1M
Stock-based compensation	$248,000

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-8.41
Book value per share	$0.96
Debt / EBITDA	0.13
Debt / equity	0.04
Long-term assets	$2.4M
Long-term liabilities	$595,000
Net cash (debt)	$35.1M
Net cash / market cap	78.69%
Net cash growth	-40.09%
Net debt / EBITDA	-3.59
Net debt / equity	-1.16
Piotroski F-Score	2
Property, plant and equipment	$2.1M
Shareholders' equity	$30.3M
Tangible book value	$30.3M
Tangible book value per share	$0.96
Total assets	$40.2M
Total cash	$36.5M
Total debt	$1.3M
Total liabilities	$9.9M
WACC	5.55%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.68
Current assets	$37.7M
Current liabilities	$9.3M
Current ratio	4.08
Net working capital	$-7.2M
Quick ratio	3.94
Working capital	$28.5M
Working capital turnover	0.86

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.28%
Dividend yield	0%
Shareholder yield	-0.28%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-95.59%
10Y return CAGR	-26.82%
10Y total return	-95.59%
150-day SMA	$1.10
1D price change	-3.52%
1M price change	14.58%
1M total return	14.58%
1W price change	-1.79%
1W total return	-1.79%
1Y price change	-10.13%
1Y return CAGR	-10.14%
1Y total return	-10.13%
20-day SMA	$1.23
200-day SMA	$1.12
3M price change	60.93%
3M total return	60.93%
3Y price change	-74.54%
3Y return CAGR	-36.61%
3Y total return	-74.54%
50-day SMA	$1.18
50-day SMA vs 200-day SMA	50over200
52-week high	$1.72
52-week high date	2025-12-22
52-week low	$0.74
52-week low date	2026-08-05
5Y price change	-82.48%
5Y return CAGR	-29.42%
5Y total return	-82.48%
6M price change	13.64%
6M total return	13.64%
All-time high	$450.00
All-time high date	2014-04-03
All-time low	$0.74
All-time low date	2026-08-05
Average true range (ATR)	$0.12
Average volume	248.8K
Beta (1Y)	0.92
Beta (2Y)	1.64
Beta (5Y)	0.27
Change from 52-week high	-20.35%
Change from 52-week low	86.37%
Change from all-time high	-99.69%
Change from all-time low	87.05%
Change from open	0%
Day's gap	-3.52%
Dollar volume	$73,473
High price	$1.37
Low price	$1.37
Monthly RSI	40.87
Open price	$1.37
Premarket change	-2.82%
Premarket close	$1.42
Premarket price	$1.38
Premarket volume	687
Previous close	$1.42
Price vs 150-day SMA	25%
Price vs 20-day SMA	12.15%
Price vs 200-day SMA	22.99%
Price vs 50-day SMA	16.82%
Relative volume	0.22
RSI	57.52
Sharpe ratio	0.14
Sharpe ratio (3Y)	-0.08
Sharpe ratio (5Y)	-0.05
Sortino ratio	0.34
Sortino ratio (3Y)	-0.05
Sortino ratio (5Y)	-0.01
Volume	53.6K
Weekly RSI	56.9
YTD price change	1.1%
YTD total return	1.1%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	31.3M
Float percentage	99.41%
Shares change (QoQ)	0.54%
Shares change (YoY)	0.28%
Shares held by insiders	0.59%
Shares held by institutions	16.85%
Shares outstanding	31.4M
Short % of float	2.26%
Short % of shares	2.24%
Short ratio	5.2 days

Deeper analysis on ATNM

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ATNM report

Is a complete ATNM research report available?

No complete published report is available for Actinium Pharmaceuticals, Inc. (ATNM) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Actinium Pharmaceuticals, Inc. (ATNM)

Price

Financial snapshot

Fair-value bridge

Latest news · ATNM

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ATNM indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ATNM

Frequently asked questions